07:11 EST Bristol Myers (BMY) falls 4% to $46.41 after stopping Phase 3 Librexia ACS trial
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers to stop Phase 3 Librexia ACS trial of milvexian
- Nike upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Scotiabank starts 10 large cap drugmakers with ‘out-of-consensus’ positive view
- Bristol Myers initiated with a Sector Perform at Scotiabank
- Pharma firms spending billions on treatments based off old drugs, Bloomberg says